Madrigal Other Non Cash Items vs Capital Expenditures Analysis
| MDGL Stock | USD 343.97 14.73 4.47% |
Madrigal Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Madrigal Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Madrigal Pharmaceuticals is a good investment. Please check the relationship between Madrigal Pharmaceuticals Other Non Cash Items and its Capital Expenditures accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.
Other Non Cash Items vs Capital Expenditures
Other Non Cash Items vs Capital Expenditures Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Madrigal Pharmaceuticals Other Non Cash Items account and Capital Expenditures. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Madrigal Pharmaceuticals' Other Non Cash Items and Capital Expenditures is -0.23. Overlapping area represents the amount of variation of Other Non Cash Items that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of Madrigal Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Madrigal Pharmaceuticals' Other Non Cash Items and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Non Cash Items of Madrigal Pharmaceuticals are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Other Non Cash Items i.e., Madrigal Pharmaceuticals' Other Non Cash Items and Capital Expenditures go up and down completely randomly.
Correlation Coefficient | -0.23 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Other Non Cash Items
Capital Expenditures
Capital Expenditures are funds used by Madrigal Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Madrigal Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most indicators from Madrigal Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Madrigal Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.At this time, Madrigal Pharmaceuticals' Selling General Administrative is quite stable compared to the past year. Sales General And Administrative To Revenue is expected to rise to 75.06 this year, although Enterprise Value Over EBITDA will most likely fall to (12.00).
Madrigal Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Madrigal Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Madrigal Pharmaceuticals fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 442.1M | 287.0M | 273.3M | 362.6M | 640.5M | 672.6M | |
| Total Stockholder Equity | 416.6M | 240.0M | 196.1M | 197.4M | 405.3M | 425.6M | |
| Common Stock Shares Outstanding | 15.4M | 15.4M | 16.5M | 17.1M | 18.7M | 19.6M | |
| Liabilities And Stockholders Equity | 442.1M | 287.0M | 273.3M | 362.6M | 640.5M | 672.6M | |
| Other Stockholder Equity | 639.6M | 665.4M | 863.5M | 1.2B | 1.7B | 1.8B | |
| Total Liab | 25.5M | 47.0M | 77.2M | 165.2M | 235.2M | 247.0M | |
| Other Current Liab | 23.6M | 44.9M | 54.6M | 91.5M | 89.5M | 93.9M | |
| Total Current Liabilities | 25.1M | 46.6M | 76.8M | 115.9M | 118.5M | 124.5M | |
| Property Plant And Equipment Net | 1.9M | 1.8M | 1.6M | 1.2M | 3.3M | 2.1M | |
| Net Debt | (46.0M) | (53.2M) | (35.5M) | (281.7M) | 17.3M | 18.1M | |
| Retained Earnings | (223.2M) | (425.5M) | (667.3M) | (962.7M) | (1.3B) | (1.3B) | |
| Accounts Payable | 1.2M | 1.0M | 21.4M | 23.8M | 28.0M | 29.4M | |
| Cash | 46.7M | 54.0M | 36.3M | 331.5M | 99.9M | 99.8M | |
| Non Current Assets Total | 1.9M | 1.8M | 1.6M | 1.2M | 3.3M | 2.4M | |
| Non Currrent Assets Other | 1.9M | 1.8M | 797K | 1.2M | 1.4M | 719.9K | |
| Cash And Short Term Investments | 439.0M | 284.1M | 270.3M | 358.8M | 634.1M | 665.8M | |
| Short Term Investments | 392.3M | 230.1M | 234.1M | 27.2M | 534.2M | 560.9M | |
| Other Current Assets | 1.2M | 2.0M | 2.7M | 2.6M | 3.2M | 3.3M | |
| Property Plant And Equipment Gross | 1.9M | 1.8M | 1.6M | 1.2M | 3.3M | 2.1M | |
| Total Current Assets | 440.2M | 285.2M | 271.7M | 361.4M | 637.3M | 669.1M | |
| Accumulated Other Comprehensive Income | 216K | 47K | (80K) | (32K) | 468K | 491.4K | |
| Non Current Liabilities Total | 361K | 468K | 387K | 49.3M | 116.7M | 122.5M | |
| Net Tangible Assets | 416.6M | 240.0M | 196.1M | 197.4M | 227.0M | 184.4M | |
| Retained Earnings Total Equity | (223.2M) | (425.5M) | (667.3M) | (962.7M) | (866.4M) | (823.1M) | |
| Capital Surpluse | 639.6M | 665.4M | 863.5M | 1.2B | 1.3B | 1.4B | |
| Property Plant Equipment | 1.2M | 1.0M | 1.6M | 601K | 691.2K | 734.4K | |
| Net Invested Capital | 416.6M | 240.0M | 196.1M | 246.7M | 520.8M | 358.2M | |
| Net Working Capital | 415.1M | 238.6M | 194.8M | 245.5M | 518.7M | 356.9M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (25.02) | Revenue Per Share 3.705 | Return On Assets (0.52) | Return On Equity (1.30) |
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.